ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

A Novel Polymer Product, APP-103, Reduces IRI-Induced Damage and Promotes Functional Improvement in Syngeneic Models of Renal Transplantation

K. Minami1, S. Bae2, H. Uehara1, J. Iske1, J. Reder3, H. Azuma4, A. Weins1, E. Van Keuren5, B. Houser3, A. El-Khal1, P. Kang2, S. Tullius1

1Brigham and Women's Hospital, Boston, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Celdara Medical, Lebanon, NH, 4Osaka Medical College, Osaka, Japan, 5Georgetown University, Washington DC, DC

Meeting: 2020 American Transplant Congress

Abstract number: LB-044

Keywords: Ischemia, Kidney, Kidney transplantation, Reactive oxygen species

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session D: Late Breaking

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • The Novel Polymer Pro-Drug APP-103 Reduces I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model
  • The Polymer Pro-Drug APP-103 Mitigates I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model.

*Purpose: Our data introduce APP-103 as a novel, non-toxic and site-activating therapeutic approach that effectively ameliorates the consequences of ischemia/reperfusion injury in solid organ transplantation.

*Methods: A key event driving inflammatory responses in ischemia/reperfusion injury (IRI) in alloimmunity and transplant outcomes is the burst of reactive oxygen species. Here, we used two IRI models to evaluate the therapeutic properties of APP-103 that exhibits high sensitivity and specificity towards the production of H2O2. APP-103 is uniquely both an antioxidant and anti-inflammatory product mitigating IRI prior to downstream alloimmune activation and the initiation of fibrotic processes. We demonstrate that APP-103 is safe, effectively promotes kidney function following IRI, and continued preclinical development is ongoing with anticipation of clinical entrance in renal transplantation in the mitigation of delayed graft function (DGF).

*Results: In a warm ischemia model, IRI was induced in the rats by clamping the left renal pedicle for 45 minutes followed by reperfusion. Control animals exhibited a dramatic increase in serum creatinine (SCrea) levels by 24 h, while animals treated with a single dose APP-103 (3 mg/kg) 10 minutes prior to IRI induction showed a significantly reduced SCrea levels. Histological analysis confirmed that treated animals were protected against IRI-induced tissue injuries. We next created a syngeneic kidney transplantation model and analyzed the therapeutic impact of APP-103 with a cold ischemia time (CIT) of 6 h. APP-103 or phosphate buffer saline (PBS) was administered IV at 15 mg/kg 1 h prior to injury and after + 2 h. Treatment with APP-103 significantly reduced SCre levels on post-operative day 1 (1.39±0.15 vs. 2.16±0.27, p=0.019). Histopathology assessment of the transplanted kidney grafts revealed tubular injury and fibrosis with extensive chronic tubule-interstitial changes, dilation of tubules, diffuse interstitial fibrosis only in vehicle-treated animals. Mechanistically, we analyzed a reduction in dihydroethidium (DHE) staining, a semi-quantitative oxidative stress indicator in the transplanted kidneys of APP-103 treated animals. In addition to a reduction in antioxidant species, kidneys from APP-103 treated animals demonstrated reduced intragraft mRNA expression of relevant pro-inflammatory cytokines.

*Conclusions: These data suggest that APP-103 represses ROS leading to a reduction of proinflammatory cytokines and improved functional graft outcomes. Thus, our results demonstrate in clinically relevant models that APP-103 alleviates IRI-associated pro-inflammatory responses by targeting the effects of H2O2.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Minami K, Bae S, Uehara H, Iske J, Reder J, Azuma H, Weins A, Keuren EVan, Houser B, El-Khal A, Kang P, Tullius S. A Novel Polymer Product, APP-103, Reduces IRI-Induced Damage and Promotes Functional Improvement in Syngeneic Models of Renal Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/a-novel-polymer-product-app-103-reduces-iri-induced-damage-and-promotes-functional-improvement-in-syngeneic-models-of-renal-transplantation/. Accessed February 27, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Penis Transplantation: First U.S. Experience.
      • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
      • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
      • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
      • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.